Participants are randomly placed into one of two groups: one receives the standard chemotherapy alone, and the other receives the same chemotherapy plus venetoclax taken by mouth each day for a set period. Treatment cycles are repeated as scheduled, and children are followed for several months to monitor their health. The main result the study looks at is overall survival, which means the length of time from the start of the study until death from any cause.

The investigational medicine, TSRA-196, is given as an intravenous (IV) infusion, meaning it is delivered directly into a vein through a small needle. It contains specially designed RNA molecules that aim to boost the body’s own production of the protective protein. The treatment is being tested to see if it can safely raise the level of this protein in the blood and improve its function.

The purpose of the study is to evaluate safety and the ability of the drug to increase protein levels after one dose and after a possible second dose. Participants receive a single infusion, then attend follow‑up visits over several months during which blood samples are taken to measure protein amounts and functional activity using an elastase inhibition assay, and health checks are performed to monitor any side effects. A second infusion may be given later, followed by the same monitoring schedule.

The purpose of the study is to evaluate the long‑term outcomes and safety of repeated adjuvant (additional) treatment with rituximab in this condition. Participants receive two infusions several weeks apart and are then followed for several months with regular clinic visits to check how they feel and to monitor any side effects.

During the follow‑up, doctors use simple rating scales such as the Clinical Global Impression – Improvement, which measures how much a person’s symptoms have gotten better, and the Clinical Global Impression – Severity, which rates how serious the illness is. Patients also complete short questionnaires about their overall health, daily functioning, and any changes in blood tests that may show immune system activity. Family members may be asked to give their view of any improvement as well.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to evaluate how well the VLA15 vaccine works in preventing Lyme disease, as well as to assess its safety and how well it is tolerated by participants. The study will also look at the immune response generated by the vaccine, which is the body’s way of defending itself against infections. Participants in the study will receive a series of injections over a period of time and will be monitored for any reactions or side effects. The study will include people aged 5 years and older who live in areas where Lyme disease is common.

Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects from the vaccine. The study aims to ensure that the vaccine is safe and effective for people of different ages, including children and adults. By participating in this study, researchers hope to gather important information that could lead to a new way to prevent Lyme disease in the future.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

After completing an earlier trial, participants may stay in the study and keep taking the medicine each day. They will visit the clinic at regular intervals where doctors will check their health, run blood tests, and ask them to fill out several questionnaires. These include a movement assessment called MDS-UPDRS, a short thinking test known as MoCA, a severity rating questionnaire (CISI-PD), a quality‑of‑life survey (PDQ-8), an anxiety and depression screen (HAD), and a questionnaire about other symptoms (NMSQ). Any side effects or abnormal lab results will be recorded, and the safety information will be compared with data from the earlier study’s active and placebo groups.

During the scan, a short‑acting medicine is given through an IV to make the heart work a little harder, allowing doctors to see how the blood vessels respond. The medicines used are Adenosine and regadenoson, both of which safely cause a temporary rise in heart workload. A small amount of a harmless radioactive substance, O15-water, is also injected so the scanner can create detailed pictures of blood flow. The amount of blood moving through the heart muscle is expressed as MBF, which helps identify areas that may not be getting enough oxygen.

The purpose of the study is to find specific numbers that can predict the chance of future major heart problems, known as MACE. Participants undergo the PET scan with the stress medicines, then are followed for several years while information about any heart attacks, deaths, or related events is recorded. This follow‑up helps determine which scan results are linked to higher or lower risk.

The main aim is to see how the level of a protein called neurofilament light chain in the cerebral spinal fluid changes over time when patients switch from Rituximab to Tolebrutinib compared with staying on Rituximab. Neurofilament light chain is a substance that can rise when nerve fibers are damaged, so measuring it helps understand disease activity.

Participants will be assigned to either continue receiving Rituximab or start taking Tolebrutinib, and they will be followed for up to two years. During this period, regular clinic visits will include blood draws, occasional spinal fluid collection, and standard brain scans to monitor any changes. The study does not involve any experimental procedures beyond the approved medications and routine testing.

The purpose of the trial is to confirm that EMP22 produces the same effect as the already approved drug Xenical® in terms of how much fat is expelled in the stool, a measure known as faecal fat excretion. This type of comparison is called pharmacodynamics, which looks at what the drug does to the body.

Healthy volunteers will take the study capsules in two separate parts. In the first part, participants will receive EMP22 and Xenical® in a single‑blind crossover design, meaning they will not know which capsule they are taking each time, but the study staff will. In the second part, the focus shifts to how the body processes the medicines, referred to as pharmacokinetics, by giving EMP16 and comparing it to Xenical®. Participants will follow a short schedule of taking the capsules, providing stool samples, and having a few blood draws to assess how the medicines work and are handled by the body.

People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.